Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centogene AG - |
RCV001809044 | SCV002059388 | uncertain significance | Intellectual disability-severe speech delay-mild dysmorphism syndrome | 2021-04-09 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003728014 | SCV004530228 | uncertain significance | not provided | 2022-11-22 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces phenylalanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 661 of the FOXP1 protein (p.Phe661Ser). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FOXP1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1333829). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt FOXP1 protein function. |